Terminated PHASE4 INTERVENTIONAL 3-arm NCT01549158

Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart Failure

Randomized, Open-Label, Blinded-Endpoint, Crossover, Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg, in Patients With Compensated Heart Failure (CHF).

Sponsor: Ferrer Internacional S.A.

Conditions Compensated Heart Failure

Interventions Furosemide-IR torasemide-IR torasemide-PR

Updated 5 times since 2017 Last updated: Apr 24, 2013 Started: Feb 29, 2012 Primary completion: Oct 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow recruitment

Other terminated trials from Ferrer Internacional S.A.

More terminations from Ferrer Internacional S.A.

This PHASE4 trial investigates Compensated Heart Failure and is currently terminated or withdrawn. Ferrer Internacional S.A. leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE4

First recorded

Feb 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ferrer Internacional S.A.

Data source: Ferrer Internacional S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain